Exploratory results from the CANTOS study showed a significant reduction in the risk of hospitalization for HF or HF-related mortality in patients treated with the IL-1β inhibitor canakinumab (Everett et al., 2019). This evidence concerns the gene IL1B and hydrops fetalis.